Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pentoxifylline,Vitamin E
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 09, 2024
Lead Product(s) : Pentoxifylline,Vitamin E
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pentoxifylline,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Poolbeg Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate
Details : Through the agreement with Silk Road Therapeutics to acquire novel topical muco-adherent formulation of Trental (pentoxifylline), for oral ulcers in patients suffering from behcet's disease.
Product Name : Trental
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 30, 2024
Lead Product(s) : Pentoxifylline,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Poolbeg Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Pentoxifylline,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP
Details : Trental-Generic (pentoxifylline) is an oral small molecule drug. It is now approved for the treatment of chronic occlusive arterial disease of the limbs.
Product Name : Trental-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 23, 2024
Lead Product(s) : Pentoxifylline,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pentoxifylline,Vitamin E,Clodronic Acid Disodium Salt
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 26, 2023
Lead Product(s) : Pentoxifylline,Vitamin E,Clodronic Acid Disodium Salt
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pentoxifylline,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Soligenix
Deal Size : Undisclosed
Deal Type : Agreement
Details : The option agreement grants Soligenix the right to acquire a novel topical formulation of SRT001 (pentoxifylline), a non-biological anti-TNF-alpha inhibitor, for the treatment of mucocutaneous ulcers in patient's suffering from Behçet's Disease (BD).
Product Name : Trental
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 05, 2023
Lead Product(s) : Pentoxifylline,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Soligenix
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Pentoxifylline,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : CSPC Ouyi Pharmaceutical Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 17, 2022
Lead Product(s) : Pentoxifylline,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : CSPC Ouyi Pharmaceutical Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pentoxifylline,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 04, 2019
Lead Product(s) : Pentoxifylline,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pentoxifylline,Colchicine
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Istanbul University - Cerrahpasa
Deal Size : Inapplicable
Deal Type : Inapplicable
Topical Pentoxifylline Gel on Behcet's Disease Oral Ulcers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 25, 2019
Lead Product(s) : Pentoxifylline,Colchicine
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Istanbul University - Cerrahpasa
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vedolizumab,Pentoxifylline
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Synergistic Effect of Vedolizumab and Pentoxifylline
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
November 02, 2016
Lead Product(s) : Vedolizumab,Pentoxifylline
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pentoxifylline,Ursodeoxycholic Acid,Enoxaparin Sodium
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Sirtex Medical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 23, 2010
Lead Product(s) : Pentoxifylline,Ursodeoxycholic Acid,Enoxaparin Sodium
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Sirtex Medical
Deal Size : Inapplicable
Deal Type : Inapplicable